AU2002309180A1 - Composition and kit for the treatment of inflammatory bowel diseases - Google Patents

Composition and kit for the treatment of inflammatory bowel diseases

Info

Publication number
AU2002309180A1
AU2002309180A1 AU2002309180A AU2002309180A AU2002309180A1 AU 2002309180 A1 AU2002309180 A1 AU 2002309180A1 AU 2002309180 A AU2002309180 A AU 2002309180A AU 2002309180 A AU2002309180 A AU 2002309180A AU 2002309180 A1 AU2002309180 A1 AU 2002309180A1
Authority
AU
Australia
Prior art keywords
kit
treatment
composition
inflammatory bowel
bowel diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002309180A
Inventor
Olle Larm
Robert Lofberg
Leif Torkvist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicarb AB
Original Assignee
Medicarb AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicarb AB filed Critical Medicarb AB
Publication of AU2002309180A1 publication Critical patent/AU2002309180A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A61K31/75—Polymers of hydrocarbons of ethene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002309180A 2002-04-24 2002-04-24 Composition and kit for the treatment of inflammatory bowel diseases Abandoned AU2002309180A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/002275 WO2003090763A1 (en) 2002-04-24 2002-04-24 Composition and kit for the treatment of inflammatory bowel diseases

Publications (1)

Publication Number Publication Date
AU2002309180A1 true AU2002309180A1 (en) 2003-11-10

Family

ID=29266746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002309180A Abandoned AU2002309180A1 (en) 2002-04-24 2002-04-24 Composition and kit for the treatment of inflammatory bowel diseases

Country Status (4)

Country Link
EP (1) EP1539192A1 (en)
CN (1) CN1627948A (en)
AU (1) AU2002309180A1 (en)
WO (1) WO2003090763A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4856948B2 (en) 2005-12-27 2012-01-18 コニカミノルタビジネステクノロジーズ株式会社 Toner for electrostatic image development
EP2581090A1 (en) * 2008-05-13 2013-04-17 Apharm S.r.l. Glycosaminoglycan oral use and compositions
US9241953B2 (en) 2008-05-13 2016-01-26 Apharm S.R.L. Glycosaminoglycan oral use and compositions
WO2010144044A1 (en) * 2009-06-10 2010-12-16 Exthera Ab Use of a composition for the treatment of mucositis
ITMI20131467A1 (en) 2013-09-06 2015-03-07 Sofar Spa USE OF A COMPOSITION INCLUDING MICRO-ORGANISMS TO INCREASE THE INTESTINAL PRODUCTION OF BUTIRRIC ACID, FOLIC ACID OR NIACINE ACID AND / OR TO REDUCE THE INTESTINAL PRODUCTION OF SUCCINIC ACID
MA39710A (en) * 2014-04-23 2015-10-29 Sofar Spa Topical composition for use in the treatment of inflammatory bowel disease
MA45327A (en) 2016-05-13 2019-03-20 Sofar Spa USE OF PROBIOTICS TO IMPROVE PROTEIN ABSORPTION
MA45288A (en) 2016-06-08 2019-04-17 Sofar Spa New medical use of probiotics
IT201600122724A1 (en) 2016-12-02 2018-06-02 Sofar Spa EXOPOLYSACCHARIDES AND USES THEREOF
IT201600127498A1 (en) 2016-12-16 2018-06-16 Sofar Spa PROBIOTICS FOR USE IN DIVERTICULOSIS AND DIVERTICULAR DISEASE
CN110312937B (en) * 2017-01-19 2023-01-10 和田孝一郎 Diagnostic agent, diagnostic method and diagnostic device for diagnosing permeability of intestinal mucosa
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
SE9602644D0 (en) * 1996-07-04 1996-07-04 Astra Ab New use
US6653294B2 (en) * 2000-02-29 2003-11-25 Food Industry Research & Development Institute Use of chitinous materials for inhibiting cellular nitric oxide production

Also Published As

Publication number Publication date
CN1627948A (en) 2005-06-15
WO2003090763A1 (en) 2003-11-06
EP1539192A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
WO2003034984A9 (en) Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1581119A4 (en) Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
HK1082256A1 (en) New compounds, compositions and methods for treatment of inflammatory diseases and conditions
EP1592384A3 (en) Cop 1 for treatment of inflammatory bowel diseases
AU2003221745A1 (en) rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
IL152127A0 (en) Probiotic compositions for the treatment of inflammatory bowel disease
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1711197A4 (en) Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
AU2003271944A1 (en) Methods for making water treatment compositions and compositions thereof
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003299441A1 (en) Nf-hev compositions and methods of use
AU2003290605A1 (en) Compositions and methods for the diagnosis and treatment of sepsis
AU2002309180A1 (en) Composition and kit for the treatment of inflammatory bowel diseases
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2003206945A1 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU2001267404A1 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase